drugset

drugset / Trial / NCT05314738

Safety and Efficacy of Corneal Cross-linking in Subjects With Keratoconus

NCT05314738 ↗

Phase 1/2 Recruiting 150 enrolled Glaukos Corporation

RandomizedParallel-groupSingle-blindTreatment

Summary

Clinical Trial to Evaluate the Safety and Efficacy of Corneal Cross-linking in Subjects with Keratoconus.

Timeline

Start: 2022-03-08
Primary completion: 2025-08
Completion: 2026-02

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Riboflavin	Other / unclassified	—	Other

Indications